[{"id":"08310589-48de-424e-82b3-d1923ffca137","acronym":"","url":"https://clinicaltrials.gov/study/NCT03302403","created_at":"2021-01-18T16:18:51.239Z","updated_at":"2024-07-02T16:36:40.277Z","phase":"","brief_title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","source_id_and_acronym":"NCT03302403","lead_sponsor":"Kang YU","biomarkers":" CLDN18 • GPC3","pipe":" | ","alterations":" CD19 positive • GPC3 positive","tags":["CLDN18 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 12/12/2020","primary_completion_date":" 12/12/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2020-10-08"}]